Hopstem Completed 40 Million Usd Series B Financing, To Develop Safe, Effective And Affordable Ipsc Cell Therapies For Global Patients
Hopstem Completed 40 Million Usd Series B Financing, To Develop Safe, Effective And Affordable Ipsc Cell Therapies For Global Patients
11/01/21, 8:00 PM
Industry
health care
Round Type
series b
After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital.
Company Info
Additional Info
CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. HOPSTEM is an innovative startup company aiming to develop safe, effective and affordable iPSC cell therapy products for global patients.